Form 4: InMed Pharmaceuticals COO Michael Woudenberg Reports Stock Option Grant

InMed Pharmaceuticals' Chief Operating Officer, Michael Woudenberg, was granted 3,750 stock options on December 20, 2024, which vest monthly over 36 months.

Summary

• Michael Woudenberg, the Chief Operating Officer of InMed Pharmaceuticals, reported a transaction on December 20, 2024.
• He was granted 3,750 employee stock options with an exercise price of $4.14.
• These options will vest in equal monthly installments over 36 months.
• The options expire on December 19, 2029.
• Following this transaction, Mr. Woudenberg now beneficially owns 7,505 derivative securities.
• The common stock of InMed was reverse split on a 1-for-20 basis on November 14, 2024, which is reflected in the reported numbers.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally positive for aligning management interests, but not a major event.

Positives

• The grant of stock options to the COO aligns his interests with the company's performance and shareholder value.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This is a standard practice for publicly traded companies to grant stock options to executives as part of their compensation packages, aligning their interests with the company's performance.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of 36 months is also typical, designed to retain talent and incentivize long-term performance.
• The exercise price of $4.14 is specific to InMed's stock price at the time of the grant and would be compared to similar companies based on their stock price and option grant policies.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the company performs well, as the executive's interests are aligned with the company's success.
• The vesting schedule encourages long-term commitment from the executive, which can be beneficial for the company's stability.

Key Dates

Keywords

stock options, insider trading, executive compensation, InMed Pharmaceuticals, Michael Woudenberg, Form 4, vesting, reverse stock split